Serological Study of the Exposure of Personnel to COVID-19 (SEROPHUGAC)

Serological Study of the Exposure of Personnel to Sars-cov-2 in an Urban Hospital Two Months After Managing an Influx of COVID Patients 19

A seroconversion test for SARS-Cov-2 will be offered to all the employees of a care institution, which has treated 240 patients hospitalized for COVID disease between 28/02 and 30/04/2020. The seroconversion test will be with a questionnaire to determine:

• whether the subject has shown signs of infection in the last 3 recent months
• if the subject has been in contact with COVID-diagnosed subjects (RT-PCR diagnosis or scanner) outside of the activity or within the professional activity (patient or colleague)
• Working conditions during the period
• The level of knowledge and respect of the barrier measures practices.
• Respect for distance during meals professional. Overall seroprevalence and stratified seroprevalence by care and administrative areas will be determined.

Study Overview

• Status: Completed
• Conditions: Sars-CoV2
• Intervention / Treatment: Diagnostic test: Sars-Cov-2 serology

• Study Type: Interventional
• Enrollment (Actual): 957
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Lyon, France, 69007
    • Centre Hospitalier St Joseph St Luc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Subject who worked at Saint Joseph Saint Luke's Hospital during the epidemic wave (male or female).

  • Free and informed consent
  • Social security affiliation

Exclusion Criteria:

• Subject refusal
• Subject on leave during the entire period

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: CoVID exposure	Diagnostic test: Sars-Cov-2 serology; Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff; Other Names: serology

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff with a seroconversion test for SARS-Cov-2	Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff	1 month

Collaborators and Investigators

• Sponsor: Centre Hospitalier Saint Joseph Saint Luc de Lyon

Publications and helpful links

General Publications

• Vivier E, Pariset C, Rio S, Armand S, Doroszewski F, Richard D, Chardon M, Romero G, Metral P, Pecquet M, Didelot A. Specific exposure of ICU staff to SARS-CoV-2 seropositivity: a wide seroprevalence study in a French city-center hospital. Ann Intensive Care. 2021 May 13;11(1):75. doi: 10.1186/s13613-021-00868-8.

Study record dates

Study Major Dates

• Study Start (Actual): June 8, 2020
• Primary Completion (Actual): July 10, 2020
• Study Completion (Actual): July 10, 2020

Study Registration Dates

• First Submitted: June 5, 2020
• First Submitted That Met QC Criteria: June 5, 2020
• First Posted (Actual): June 9, 2020

Study Record Updates

• Last Update Posted (Actual): April 4, 2024
• Last Update Submitted That Met QC Criteria: April 3, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: SEROPHUGAC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No